Articles tagged "Hepatitis C"

2015 American Transplant Congress
Screening Recipients of Increased Risk Donor Organs: A Multicenter Study
N. Theodoropoulos,¹ K. Brizendine,² M. Ison.³
¹Infectious Diseases, The Ohio State University, Columbus, OH; ²Infectious Disease, Cleveland Clinic, Cleveland, OH; ³Infectious Diseases/Organ Transplantation, Northwestern University, Chicago, IL.
Purpose: Policy mandates post-transplant (tx) evaluation of recipients of increased risk donor organs (ROIRDO). PHS guidelines recommend that screening include HIV & hepatitis C virus…
2015 American Transplant Congress
End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR
B. Ismail,¹ X. Zervos,¹ P. Bejarano,² M. Waton,¹ D. Beltran,³ D. Sears,¹ A. Tzakis.¹
¹Liver Transplant, Cleveland Clinic Florida, Weston, FL; ²Pathology, Cleveland Clinic Florida, Weston, FL; ³Pharmacy, Cleveland Clinic Florida, Weston, FL.
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…
2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
J. O'Leary,¹ R. Brown,² K. Reddy,³ A. Kuo,⁴ G. Morelli,⁵ R. Stravitz,⁶ G. Everson,⁷ C. Durand,⁸ H. Vargas,⁹ P. Kwo,¹⁰ C. Frenette,¹¹ J. Peter,¹² M. Vainorius,¹² L. Akushevich,¹² D. Nelson,⁵ M. Fried,¹² N. Terrault.¹³
¹Baylor University Medical Center, TX; ²Columbia University, NY; ³University of Pennsylvania, PA; ⁴UCSD, CA; ⁵University of Florida, Gainesville, Gainesville, FL; ⁶Virginia Commonwealth University, VA; ⁷University of Colorado, CO; ⁸Johns Hopkins, MD; ⁹Mayo Clinic, AZ; ¹⁰Indiana University, IL; ¹¹Scipps Clinic, CA; ¹²University of North Carolina, NC; ¹³UCSF, CA.
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…
2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
X. Zervos,¹ D. Beltran,² B. Ismail,¹ M. Watson,¹ D. Sears,¹ A. Tzakis.¹
¹Liver Transplant, Cleveland Clinic Florida, Weston, FL; ²Pharmacy, Cleveland Clinic Florida, Weston, FL.
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…
2015 American Transplant Congress
Changes in Utilization, Discard, and Outcomes Associated With Hepatitis C (+) Donor Livers in the Era of Direct Acting Anti-Retroviral Therapy
M. Bowring, L. Kucirka, X. Luo, A. Massie, D. Segev, C. Durand.
Johns Hopkins University, Baltimore, MD.
While 45% of liver candidates are hepatitis C (HCV) (+) and might benefit from an HCV (+) donor liver, only 7.1% receive one, and HCV…
2015 American Transplant Congress
Pretransplant Hepatitis B Viral Infection Increased Risk of Death After Kidney Transplantation
J. Lee,¹ J.-H. Cho,² J. An,³ C.-D. Kim,² C. Ahn,⁴ I. Jung,³ D. Han, C. Lim,³ Y. Kim,⁴ Y. Kim, J. Lee.³
¹Internal Medicine, Hallym University Hangang Sacred Heart Hospital, Seoul, Republic of Korea; ²Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea; ³Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea; ⁴Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ⁵Surgery, Ulsan University Seoul Asan Medical Center, Seoul, Republic of Korea.
Clinical outcomes have not been well evaluated in kidney transplant recipients (KTRs) with hepatitis B virus (HBV). Here, we aimed to investigate the recent posttransplant…
2015 American Transplant Congress
The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis
S. Munoz,¹ D. Reich,² K. Rothstein.¹
¹Div of Hepatology, Liver Failure Unit, Hanemann University Hospital, Philadelphia, PA; ²Liver, Kidney and Pancreas Transplant Program, Hahnemann University Hospital, Philadelphia, PA.
The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…
2015 American Transplant Congress
Pre-Liver Transplant Urinary Proteome Analysis Does Not Predict Development of Chronic Kidney Disease After Transplantation
D. Milongo,^1,3 J. Bascands,^2,3,4 L. Esposito,^1,3 L. Lavayssière,^1,3 A. Del Bello,^1,3 L. Rostaing,^1,3,5 J. Schanstra,^2,3,4 N. Kamar.^1,3,5
¹Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France; ³Université Toulouse III Paul-Sabatier, Toulouse, France; ⁴Plateau de Protéomique des Liquides Biologiques, Institut of Cardiovascular and Metabolic Disease, Toulouse, France; ⁵INSERM U1043, IFR–BMT, Toulouse, France.
Background and aims: Chronic kidney disease (CKD) is a common complication after liver transplantation. Kidney biopsies cannot be easily performed before liver transplantation to predict…